DAX-044 in Adults With Advanced Solid Tumours: a First-in-human Study of Safety, Dose and Early Anti-cancer Activity.
A Phase 1 First-in-human Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumour Activity of Intravenous DAX-044 in Adults With Advanced Solid Tumours.
This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety and tolerability of DAX-044 as monotherapy, and to determine its maximum tolerated dose, in adults with advanced solid tumours.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and anti-tumour activity of DAX-044, a targeted, potency-optimised interleukin-12 (IL-12) immunocytokine, as monotherapy in adults with advanced solid tumours.
Part 1 (dose escalation) will evaluate DAX-044 monotherapy across planned dose levels, using a Bayesian optimal interval (BOIN) design to determine the maximum tolerated dose (MTD). Participants with any of the eligible tumour types are enrolled together into dose-level cohorts. Each participant remains at their allocated dose level; escalation occurs between cohorts only. Additional participants may be enrolled into backfill cohorts at dose levels already cleared for safety.
Part 2 (dose expansion) will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts.
In both parts, DAX-044 is given by intravenous infusion on Day 1 of each 21-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent or sponsor termination, to a maximum of 24 months.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Iva Nikolic
- 電話番号:+61 3 9067 5625
- メール:clinops@audax.bio
研究連絡先のバックアップ
- 名前:Joanne Yan
- 電話番号:+61 3 9067 5625
- メール:clinops@audax.bio
研究場所
-
-
Western Australia
-
Nedlands、Western Australia、オーストラリア、6009
- Linear Clinical Research Ltd
-
コンタクト:
- Desi du Plessis
- 電話番号:+61 8 63825100
- メール:actcstartup@linear.org.au
-
主任研究者:
- Timothy Guy Humphries
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged at least 18 years.
- Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer, gastric or gastro-oesophageal junction adenocarcinoma, squamous cell carcinoma of the head and neck, melanoma other than ocular or uveal, triple-negative breast cancer, castrate-resistant prostate cancer (CRPC), microsatellite stable colorectal cancer, pancreatic ductal adenocarcinoma, or epithelial ovarian cancer. Tumour-type-specific requirements for prior therapy also apply.
- Measurable disease by RECIST v 1.1, except CRPC, which may be measurable or non-measurable.
- At least 1 prior line of systemic standard-of-care therapy, with radiographic progression on or after the last line received. CRPC with non-measurable disease must instead show progression of PSA.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy greater than 3 months.
- Able to provide pre-treatment tumour tissue, either archival or as a fresh biopsy.
- Adequate organ function within 14 days before first dose, including absolute neutrophil count greater than or equal to 1.5 x 10^9/L, platelets greater than or equal to 100 x 10^9/L, haemoglobin greater than or equal to 9 g/dL, bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), transaminases less than or equal to 3 times the ULN (5 times the ULN if liver metastases are present), and creatinine clearance greater than or equal to 50 mL/min.
- Agreement to use contraception according to the protocol.
Exclusion Criteria:
- Pregnant, breast-feeding, or planning to become pregnant during the study.
- Any investigational medicinal product within 30 days, before Cycle 1 Day 1.
- Part 1 only: more than 4 prior lines of systemic chemotherapy in the advanced or metastatic setting. Part 2 instead applies tumour-type-specific requirements for prior lines of therapy.
- Uncontrolled brain metastases.
- Active or past autoimmune disease or immunodeficiency.
- Idiopathic pulmonary fibrosis, organising pneumonia, drug-induced or idiopathic pneumonia, or evidence of active pneumonia at screening.
- Severe cardiovascular disease within 6 months.
- Significant surgical procedures, other than diagnostic surgery, within 4 weeks before the start of study treatment, or expected to require significant surgery during the study period.
- Known human immunodeficiency virus infection or current active hepatitis B or hepatitis C. Participants with prior HBV infection with negative HBV DNA are eligible. Participants clinically cured of hepatitis C, at least 12 weeks after completing antiviral treatment, are eligible.
- History of life-threatening toxicity related to prior immune therapy, for example an inhibitor of PD-1 or PD-L1, an anti-CTLA-4 agent, or any other drug targeting T-cell activation or immune checkpoint pathways.
- A live virus vaccine within the 4 weeks before Cycle 1 Day 1, or plans to receive a live virus vaccine during the study.
- Corrected QT interval using Fridericia correction greater than 470 milliseconds.
- Prior treatment with DAX-044 or any interleukin-12-based agent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Part 1 - DAX-044 Monotherapy Dose Escalation
DAX-044 administered at ascending dose levels to participants with advanced solid tumours, to assess safety and tolerability and determine the maximum tolerated dose (MTD). Dose escalation follows a Bayesian optimal interval (BOIN) design. |
DAX-044 monotherapy |
|
実験的:Part 2 - DAX-044 Monotherapy Dose Expansion in Tumour-Specific Cohorts
Part 2 will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts. |
DAX-044 monotherapy |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v6.0
時間枠:Up to 24 months
|
Up to 24 months
|
|
Maximum Tolerated Dose (MTD) of DAX-044 Based on Dose-Limiting Toxicities (DLTs) (Part 1)
時間枠:Up to 24 months
|
Up to 24 months
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Serum Concentrations of DAX-044
時間枠:Up to 24 months
|
Up to 24 months
|
|
Maximum Observed Serum Concentration (Cmax) of DAX-044
時間枠:Up to 24 months
|
Up to 24 months
|
|
Time to Maximum Observed Serum Concentration (Tmax) of DAX-044
時間枠:Up to 24 months
|
Up to 24 months
|
|
Trough Serum Concentration (Ctrough) of DAX-044
時間枠:Up to 24 months
|
Up to 24 months
|
|
Area Under the Serum Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of DAX-044
時間枠:Up to 24 months
|
Up to 24 months
|
|
Terminal Half-Life (t1/2) of DAX-044
時間枠:Up to 24 months
|
Up to 24 months
|
|
Clearance (CL) of DAX-044
時間枠:Up to 24 months
|
Up to 24 months
|
|
Number of Participants With Anti-Drug Antibodies (ADA) to DAX-044
時間枠:Up to 24 months
|
Up to 24 months
|
|
Objective Response Rate (ORR) as Assessed by the Investigator per RECIST 1.1
時間枠:Up to 24 months
|
Up to 24 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- DAX-044-2601
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。